SK30298A3 - Cell-cycle checkpoint genes - Google Patents

Cell-cycle checkpoint genes Download PDF

Info

Publication number
SK30298A3
SK30298A3 SK302-98A SK30298A SK30298A3 SK 30298 A3 SK30298 A3 SK 30298A3 SK 30298 A SK30298 A SK 30298A SK 30298 A3 SK30298 A3 SK 30298A3
Authority
SK
Slovakia
Prior art keywords
polypeptide
rad3
atr
protein
seq
Prior art date
Application number
SK302-98A
Other languages
English (en)
Slovak (sk)
Inventor
Anthony Michael Carr
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Publication of SK30298A3 publication Critical patent/SK30298A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SK302-98A 1995-09-06 1996-09-06 Cell-cycle checkpoint genes SK30298A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9518220.0A GB9518220D0 (en) 1995-09-06 1995-09-06 Checkpoint gene
CZ1998656A CZ292808B6 (cs) 1995-09-06 1996-09-06 ATR polypeptid, polynukleotid, který jej kóduje, způsoby jejich detekce, vektor a protilátka
PCT/GB1996/002197 WO1997009433A1 (fr) 1995-09-06 1996-09-06 Genes de point de controle a cycle cellulaire

Publications (1)

Publication Number Publication Date
SK30298A3 true SK30298A3 (en) 2000-04-10

Family

ID=25746866

Family Applications (1)

Application Number Title Priority Date Filing Date
SK302-98A SK30298A3 (en) 1995-09-06 1996-09-06 Cell-cycle checkpoint genes

Country Status (13)

Country Link
EP (1) EP0856058B1 (fr)
JP (1) JPH11511984A (fr)
CN (1) CN1201492A (fr)
AU (1) AU730220B2 (fr)
BR (1) BR9610168A (fr)
CA (1) CA2231190A1 (fr)
CZ (1) CZ292808B6 (fr)
GB (1) GB9518220D0 (fr)
IL (1) IL123553A0 (fr)
NO (1) NO980957L (fr)
PL (1) PL325427A1 (fr)
SK (1) SK30298A3 (fr)
WO (1) WO1997009433A1 (fr)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1199420A (zh) * 1995-11-16 1998-11-18 艾科斯有限公司 细胞周期关卡与pik相关的激酶材料和方法
GB9718952D0 (en) * 1997-09-05 1997-11-12 Medical Res Council Mammalian chk1 effector cell cycle checkpoint protein kinase materials and methods
WO1999042596A2 (fr) 1998-02-23 1999-08-26 Icos Corporation Phosphodiesterase 10
US6479256B1 (en) 1998-03-04 2002-11-12 Icos Corporation Lectomedin materials and methods
US6071691A (en) * 1998-04-27 2000-06-06 Oregon Health Science University Materials and methods for modulating differentiation
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
ES2439645T3 (es) 1999-04-09 2014-01-24 Zoetis P&U Llc Bacteria pasteurelácea atenuada que tiene una mutación en un gen de virulencia
US6670167B1 (en) * 1999-11-01 2003-12-30 Agouron Pharmaceuticals, Inc. Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
US6344549B1 (en) 1999-10-14 2002-02-05 Icos Corporation ATR-2 cell cycle checkpoint
AU783082B2 (en) 1999-10-22 2005-09-22 Pharmacia & Upjohn Company Drosophila G protein coupled receptors, nucleic acids, and methods related to the same
AU1927801A (en) 1999-11-24 2001-06-04 Pharmacia & Upjohn Company G protein-coupled receptor-like receptors and modulators thereof
US6498026B2 (en) 2000-02-25 2002-12-24 Hercules Incorporated Variant galactose oxidase, nucleic acid encoding same, and methods of using same
AU2001274894A1 (en) 2000-05-22 2001-12-03 Pharmacia And Upjohn Company Novel matrix metalloproteinases
US6686449B2 (en) 2000-06-30 2004-02-03 Pharmacia & Upjohn Company Mutant presenilin 1 polypeptides
EP1307551A2 (fr) 2000-07-05 2003-05-07 PHARMACIA & UPJOHN COMPANY Canaux ioniques humains
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7098007B2 (en) 2001-08-22 2006-08-29 California Institute Of Technology Cloning and functional assays of Xenopus ATR
EP1543119A2 (fr) * 2002-02-13 2005-06-22 University Of Rochester Procede d'inhibition de l'activite de la proteine virale r de vih-1 et l'infectivite de vih-1 utilisant des inhibiteurs d'atr ou de rad17
EP2287192B1 (fr) 2002-11-15 2015-08-26 Novartis Vaccines and Diagnostics, Inc. Procédés de prévention et de traitement des métastases de cancer et perte osseuse associée aux métastases de cancer
WO2004070062A2 (fr) * 2003-02-04 2004-08-19 Wyeth Compositions et techniques de diagnostic et de traitement de cancers
US7541158B2 (en) 2004-04-14 2009-06-02 Monell Chemical Senses Center Taste receptors of the T1R family from domestic dog
EP2546260B1 (fr) 2004-05-24 2015-07-15 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Vaccin oral vivant pour la protection contre le sérotype 1 de shigella dysenteriae
US20060134698A1 (en) 2004-12-20 2006-06-22 Evanston Northwestern Healthcare Research Institute Methods for treating cardiac disease by modifying an N-terminal domain of troponin I
EP1912675B1 (fr) 2005-07-25 2014-02-12 Emergent Product Development Seattle, LLC Reduction de lymphocytes b au moyen de molecules de liaison specifique de cd37 et specifique de cd20
WO2007081879A2 (fr) 2006-01-05 2007-07-19 Novartis Ag Méthodes pour prévenir et traiter des métastases de cancer et des pertes osseuses associées à des métastases de cancer
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
WO2009047567A1 (fr) * 2007-10-10 2009-04-16 University Of Sheffield Essai pour identifier des agents qui inhibent les voies atr et/ou dna-pk
JP6013733B2 (ja) 2008-04-11 2016-10-25 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｃｄ３７免疫治療薬および二機能性化学療法薬とのその組合せ
KR20170091801A (ko) 2008-10-02 2017-08-09 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Ｃｄ86 길항제 다중-표적 결합 단백질
EP2516467A2 (fr) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprenant des antagonistes de tnf-alpha et il-6 et leurs procédés d'utilisation
JP5856073B2 (ja) 2009-12-29 2016-02-09 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｒｏｎ結合構築体およびその使用方法
RU2447899C2 (ru) 2010-05-27 2012-04-20 Михаил Валентинович Филатов Композиция для лечения гепатита с и способ лечения гепатита с
CN104685060B (zh) 2012-07-13 2019-11-01 凯利斯塔公司 生物精炼系统、其方法和组合物
WO2014074886A1 (fr) 2012-11-09 2014-05-15 Calysta Energy, Inc. Compositions et procédés de production biologique de dérivés d'acides gras
CN105378077A (zh) 2013-06-18 2016-03-02 凯利斯塔公司 用于使用乳酸脱氢酶转化体从c1化合物以生物方式产生乳酸的组合物和方法
US10196444B2 (en) 2013-07-29 2019-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
CN106062176A (zh) 2014-01-02 2016-10-26 特雷里斯公司 用于在氢营养微生物中生物制备氨基酸的组合物和方法
KR20160107202A (ko) 2014-01-16 2016-09-13 칼리스타, 인코포레이티드 탄수화물-농축된 재조합 미생물
US20170247692A1 (en) 2014-02-07 2017-08-31 Effector Therapeutics, Inc. Compositions and methods for treating neurological disorders
CA2938592A1 (fr) 2014-02-07 2015-08-13 Effector Therapeutics, Inc. Methodes de traitement de maladies fibreuses
BR112016021345A8 (pt) 2014-03-17 2022-07-05 Tapimmune Inc Composições de vacina de molécula de ácido nucleico e usos das mesmas
BR112016026562A2 (pt) 2014-05-15 2017-08-15 Calysta Inc Métodos para produção biológica de compostos de cadeia de carbono muito longa
CA2956545A1 (fr) 2014-08-04 2016-02-11 Fred Hutchinson Cancer Research Center Immunotherapie par cellules t specifiques de la wt-1
MX2017005344A (es) 2014-10-27 2017-08-15 Hutchinson Fred Cancer Res Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
AU2016258183A1 (en) 2015-05-06 2017-11-16 Trelys, Inc. Compositions and methods for biological production of methionine
WO2016187486A1 (fr) 2015-05-19 2016-11-24 Fred Hutchinson Cancer Research Center Biormarqueurs et leurs utilisations pour choisir un traitement contre le cancer du pancréas
KR20180053322A (ko) 2015-09-21 2018-05-21 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
EP3394092A1 (fr) 2015-12-23 2018-10-31 Fred Hutchinson Cancer Research Center Récepteurs des cellules t à forte affinité et leurs utilisations
US20170191136A1 (en) 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
EP3402878A1 (fr) 2016-01-11 2018-11-21 Zoetis Services LLC Nouvelles compositions vaccinales à protection croisée pour le virus de la diarrhée épidémique porcine
US11723962B2 (en) 2016-05-04 2023-08-15 Fred Hutchinson Cancer Center Cell-based neoantigen vaccines and uses thereof
WO2017193104A1 (fr) 2016-05-06 2017-11-09 Fred Hutchinson Cancer Research Center Immunothérapie de lymphocytes t spécifique de mart-1
EP3516044A4 (fr) 2016-09-23 2020-03-11 Fred Hutchinson Cancer Research Center Tcr spécifiques de l'antigène ha-1 d'histocompatibilité (h) mineure et ses utilisations
JP2019536471A (ja) 2016-09-27 2019-12-19 セロ・セラピューティクス・インコーポレイテッドＣＥＲＯ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． キメラエンガルフメント受容体分子
CA3042890A1 (fr) 2016-11-14 2018-05-17 Fred Hutchinson Cancer Research Center Tcr specifiques d'un antigene t de polyomavirus a cellules de merkel a haute affinite et leurs utilisations
CN110072547B (zh) 2016-12-14 2024-04-30 硕腾服务有限责任公司 断奶前对抗欧洲猪繁殖与呼吸综合征(prrs)病毒株的有效疫苗接种
WO2018148567A1 (fr) 2017-02-09 2018-08-16 Fred Hutchinson Cancer Research Center Biomarqueurs et leurs utilisations permettant la sélection d'une intervention d'immunothérapie
EP3595708A4 (fr) 2017-03-15 2020-12-16 Fred Hutchinson Cancer Research Center Tcr spécifiques de mage-a1 à haute affinité et leurs utilisations
US10780119B2 (en) 2017-05-24 2020-09-22 Effector Therapeutics Inc. Methods and compositions for cellular immunotherapy
IL272103B1 (en) 2017-07-20 2024-06-01 Aptevo Res & Development Llc Antigen-binding proteins that bind to 5T4 and 4-1BB, as well as compositions and methods for treating cancer related to them
WO2019055862A1 (fr) 2017-09-14 2019-03-21 Fred Hutchinson Cancer Research Center Récepteurs de lymphocytes t à haute affinité et leurs utilisations
JP7286658B2 (ja) 2017-09-26 2023-06-05 セロ・セラピューティクス・インコーポレイテッド キメラエンガルフメント受容体分子および使用方法
WO2019109047A1 (fr) 2017-12-01 2019-06-06 Fred Hutchinson Cancer Research Center Protéines de liaison spécifiques à 5t4 et leurs utilisations
KR102476887B1 (ko) 2017-12-20 2022-12-13 하버 바이오메드 (상하이) 컴퍼니 리미티드 Ctla-4에 결합하는 항체 및 이의 용도
WO2019140278A1 (fr) 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunothérapie ciblant des antigènes du facteur de liaison du noyau
US20200405762A1 (en) 2018-02-12 2020-12-31 Fred Hutchinson Cancer Research Center Cyclin a1 specific t cell receptors and uses thereof
EP3759130A1 (fr) 2018-02-26 2021-01-06 Fred Hutchinson Cancer Research Center Compositions et méthodes pour immunothérapie cellulaire
CN112218886A (zh) 2018-03-28 2021-01-12 森罗治疗公司 嵌合吞噬受体的表达载体、基因修饰的宿主细胞及其用途
WO2019191340A1 (fr) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Compositions d'immunothérapie cellulaire et utilisations associées
EP3774864A1 (fr) 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Récepteurs d'engloutissement chimériques et leurs utilisations pour des maladies neurodégénératives
US20210087251A1 (en) 2018-03-28 2021-03-25 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
US20210223248A1 (en) 2018-06-01 2021-07-22 Fred Hutchinson Cancer Research Center Biomarkers, uses thereof for selecting immunotherapy intervention, and immunotherapy methods
WO2020139974A1 (fr) 2018-12-27 2020-07-02 Calysta, Inc. Méthanotroph3s à glycogène nul et leurs utilisations
KR20210130189A (ko) 2019-02-20 2021-10-29 프레드 헛친슨 켄서 리서치 센터 Ras 신항원에 특이적인 결합 단백질 및 이의 용도
JP2022525099A (ja) 2019-03-11 2022-05-11 フレッド ハッチンソン キャンサー リサーチ センター 高アビディティｗｔ１ｔ細胞受容体とその使用
CN114555790A (zh) 2019-08-20 2022-05-27 弗雷德哈钦森癌症研究中心 Wt-1特异性t细胞免疫疗法
WO2021067875A1 (fr) 2019-10-03 2021-04-08 Cero Therapeutics, Inc. Récepteurs tim4 chimériques et leurs utilisations
BR112022013725A2 (pt) 2020-01-13 2022-10-11 Aptevo Res & Development Llc Formulações para agentes terapêuticos proteicos
US20230151102A1 (en) 2020-01-13 2023-05-18 Aptevo Research And Development Llc Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
WO2021178637A1 (fr) 2020-03-05 2021-09-10 Iowa State University Research Foundation, Inc. Compositions immunogènes et vaccinales dirigées contre le sars-cov-2
WO2022036285A1 (fr) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Compositions et méthodes de traitement du cancer à l'aide de récepteurs tim chimériques en association avec des inhibiteurs de la poly(adp-ribose)polymérase
WO2022036265A1 (fr) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Récepteurs chimériques tim et leurs utilisations
WO2022036287A1 (fr) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Récepteurs chimériques anti-cd72 et utilisations de ceux-ci
WO2022066973A1 (fr) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunothérapie ciblant les antigènes pbk ou oip5
CN116724053A (zh) 2020-09-24 2023-09-08 弗雷德哈钦森癌症中心 靶向sox2抗原的免疫治疗
WO2022072431A1 (fr) 2020-09-30 2022-04-07 Zoetis Services Llc Nouvelles souches de pasteurella multocida et vaccins à délétions d'hyca et de nanp
WO2022076353A1 (fr) 2020-10-06 2022-04-14 Fred Hutchinson Cancer Research Center Compositions et procédés de traitement de la maladie associée à l'expression de mage-a1
MX2023009910A (es) 2021-02-26 2023-11-09 Kelonia Therapeutics Inc Vectores lentivirales dirigidos a los linfocitos.
CN115216451A (zh) 2021-04-16 2022-10-21 硕腾服务有限责任公司 伪狂犬病病毒疫苗
AU2022276523A1 (en) 2021-05-21 2024-01-18 Aptevo Research And Development Llc Dosing regimens for protein therapeutics
WO2023010097A1 (fr) 2021-07-28 2023-02-02 Cero Therapeutics, Inc. Récepteurs tim4 chimériques et leurs utilisations
CN118267462A (zh) 2022-12-29 2024-07-02 硕腾服务有限责任公司 接种猪以抗伪狂犬病病毒的方法
WO2024148328A2 (fr) 2023-01-06 2024-07-11 Aptevo Research And Development Llc Molécules de liaison pd-l1 et cd40 bispécifiques et leurs utilisations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1199420A (zh) * 1995-11-16 1998-11-18 艾科斯有限公司 细胞周期关卡与pik相关的激酶材料和方法

Also Published As

Publication number Publication date
PL325427A1 (en) 1998-07-20
GB9518220D0 (en) 1995-11-08
BR9610168A (pt) 1998-08-11
NO980957L (no) 1998-05-05
NO980957D0 (no) 1998-03-05
JPH11511984A (ja) 1999-10-19
CZ65698A3 (cs) 2000-01-12
IL123553A0 (en) 1998-10-30
EP0856058B1 (fr) 2006-07-26
CN1201492A (zh) 1998-12-09
CZ292808B6 (cs) 2003-12-17
AU730220B2 (en) 2001-03-01
CA2231190A1 (fr) 1997-03-13
WO1997009433A1 (fr) 1997-03-13
AU6884696A (en) 1997-03-27
EP0856058A1 (fr) 1998-08-05

Similar Documents

Publication Publication Date Title
EP0856058B1 (fr) Genes de point de controle a cycle cellulaire
CA2119443C (fr) Cycline e humaine
JP3091769B2 (ja) プロテインキナーゼ
US6218136B1 (en) Methods of the identification of pharmaceutically active compounds
JP4418103B2 (ja) 新規なヒトチェックポイントキナーゼ、ｈＣＤＳ１、組成物および方法
AU745504B2 (en) Disruption of the mammalian Rad51 protein and disruption of proteins that associate with mammalian Rad51 for hindering cell proliferation
US20030077262A1 (en) Methods and compositions for modulating apoptosis
EP0690874B1 (fr) Substances et procedes relatifs a des proteines qui ont une interaction avec la kinase caseine i
US7049395B2 (en) Anti-inflammatory compounds and uses thereof
US6218515B1 (en) Cyclin E variants and use thereof
EP1263939B1 (fr) Proteine kinase 18477 et utilisations de celle-ci
JP2001510684A (ja) アッセイ、治療法及び治療手段
JPH07505057A (ja) プロテインキナーゼ
US6632936B2 (en) Cell-cycle checkpoint genes
US20060205020A1 (en) Cell-cycle checkpoint genes
RU2252256C2 (ru) ГОМОЛОГИ (ATR) ПОЛИПЕПТИДА rad3, ПОЛИНУКЛЕОТИДЫ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И МАТЕРИАЛЫ
JP2001508868A (ja) 細胞ｄｎａ 修復活性の調節に関するアッセイ、剤、治療及び診断
AU676137C (en) Human cyclin E
US6365372B1 (en) SNF2 related CBP activator protein (SRCAP)
JP2003503069A (ja) 新規キナーゼおよびその使用
US20060057669A1 (en) Inactive transcription factor tif-ia and uses thereof
MXPA98001699A (en) Control point genes of the celu cycle